top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Research Focus Areas for CAR-T

By definition, CAR-T cell therapy modifies a patient's T cells in order to target cancer cells, using a special receptor called a chimeric antigen receptor (CAR). These engineered T cells are then multiplied and infused back into the patient to attack cancer cells. It's primarily used for some blood cancers and is under research for other cancer types (National Cancer Institute). Below, we feature Novartis' CAR-T cell therapy key research areas, which aim to advance the development of this treatment further.

Novartis Key CAR-T Research Areas

FIG. 1. Novartis Key CAR-T Research Areas. Key areas for research in both hematologic and solid tumor CAR-T cell therapy.

Identify new tumor targets

  • Blood cancers: BCMA, CD22, and CD123

  • Solid tumors: EGFRv3, et al.

Reduce the immunosuppressive effect on the tumor microenvironment

  • Addition of checkpoint inhibitor

  • Enhance persistence and response

Enhance CAR-T persistence and response through

  • Dual receptor chimeric antigen receptors (CARs)

  • New costimulatory domains

  • B-cell receptor (BCR) signaling inhibitors

  • Reduce toxic on-target and off-target effects

  • Reduce off-target effects [e.g., cytokine release syndrome (CRS)]

    • Tocilizumab administration

Investigate new technologies

  • New technologies may improve the therapy

  • Natural killer (NK) cell receptors

  • Gamma/delta T cells

  • in vivo CAR-T cells

Explore allogeneic off-the-shelf technology

  • Simplifies manufacturing process

  • Explore gene-editing tools

    • CRISPR/Cas9 and RNAi

Are you a CRO, CMO, or Biopharma vendor? Our list of 100's of biopharma companies with cell therapy products would be perfect for your sales and business development activities. Access our free report here:


Article History:

2/1/2024 - EJV

This article is not investment or legal advice.


bottom of page